159 related articles for article (PubMed ID: 8221569)
21. Does the revised International Federation of Gynecology and Obstetrics staging system for endometrial cancer lead to increased discrimination in patient outcomes?
Cooke EW; Pappas L; Gaffney DK
Cancer; 2011 Sep; 117(18):4231-7. PubMed ID: 21387282
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data.
Polterauer S; Vergote I; Concin N; Braicu I; Chekerov R; Mahner S; Woelber L; Cadron I; Van Gorp T; Zeillinger R; Castillo-Tong DC; Sehouli J
Int J Gynecol Cancer; 2012 Mar; 22(3):380-5. PubMed ID: 22266934
[TBL] [Abstract][Full Text] [Related]
23. Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD.
Chekerov R; Braicu I; Castillo-Tong DC; Richter R; Cadron I; Mahner S; Woelber L; Marth C; Van Gorp T; Speiser P; Zeillinger R; Vergote I; Sehouli J
Int J Gynecol Cancer; 2013 Feb; 23(2):268-75. PubMed ID: 23358178
[TBL] [Abstract][Full Text] [Related]
24. The validity and significance of substages of advanced ovarian cancer.
Partridge EE; Gunter BC; Gelder MS; Alvarez RD; Soong SJ; Austin JM; Kilgore LC
Gynecol Oncol; 1993 Feb; 48(2):236-41. PubMed ID: 8428697
[TBL] [Abstract][Full Text] [Related]
25. Survival analysis of revised 2013 FIGO staging classification of epithelial ovarian cancer and comparison with previous FIGO staging classification.
Paik ES; Lee YY; Lee EJ; Choi CH; Kim TJ; Lee JW; Bae DS; Kim BG
Obstet Gynecol Sci; 2015 Mar; 58(2):124-34. PubMed ID: 25798426
[TBL] [Abstract][Full Text] [Related]
26. FIGO 1988 versus 2009 staging for endometrial carcinoma: a comparative study on prediction of survival and stage distribution according to histologic subtype.
Haltia UM; Bützow R; Leminen A; Loukovaara M
J Gynecol Oncol; 2014 Jan; 25(1):30-5. PubMed ID: 24459578
[TBL] [Abstract][Full Text] [Related]
27. Stage I and II Endometrial Adenocarcinoma: Analysis of 2009 FIGO Staging Revision and Impact on Survival by Adjuvant Therapy.
Cahan B; Kim JH; Schultheiss TE; Wong JYC; Chen YJ
Am J Clin Oncol; 2018 Mar; 41(3):302-306. PubMed ID: 26886945
[TBL] [Abstract][Full Text] [Related]
28. Validation of Revised FIGO Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum Based on a Single Histological Type.
Toptas T; Pestereli E; Erol O; Bozkurt S; Erdogan G; Simsek T
Int J Gynecol Cancer; 2016 Jul; 26(6):1012-9. PubMed ID: 27206284
[TBL] [Abstract][Full Text] [Related]
29. [Impact of 2009 FIGO staging system on the diagnostic value of preoperative MRI staging of endometrial carcinoma].
Yu XD; Ouyang H; Lin M; Zhou CW; Zhang R
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):692-6. PubMed ID: 22340052
[TBL] [Abstract][Full Text] [Related]
30. Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study.
Fauvet R; Boccara J; Dufournet C; David-Montefiore E; Poncelet C; Daraï E
Cancer; 2004 Mar; 100(6):1145-51. PubMed ID: 15022280
[TBL] [Abstract][Full Text] [Related]
31. Rationality of FIGO 2018 IIIC restaging of cervical cancer according to local tumor size: A cohort study.
Duan H; Li H; Kang S; Zhao H; Chen B; Wang L; Li P; Wang Y; Wang W; Lang J; Liu P; Chen C
Acta Obstet Gynecol Scand; 2023 Aug; 102(8):1045-1052. PubMed ID: 37338046
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of patients with uterine serous carcinoma using the revised FIGO staging system.
Seward S; Ali-Fehmi R; Munkarah AR; Semaan A; Al-Wahab ZR; Elshaikh MA; Cote ML; Morris RT; Bandyopadhyay S
Int J Gynecol Cancer; 2012 Mar; 22(3):452-6. PubMed ID: 22274544
[TBL] [Abstract][Full Text] [Related]
33. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S
Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
[TBL] [Abstract][Full Text] [Related]
34. The validity and significance of substage IIIC by node involvement in epithelial ovarian cancer: impact of nodal metastasis on patient survival.
Kanazawa K; Suzuki T; Tokashiki M
Gynecol Oncol; 1999 May; 73(2):237-41. PubMed ID: 10329040
[TBL] [Abstract][Full Text] [Related]
35. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer.
Makar AP; Baekelandt M; Tropé CG; Kristensen GB
Gynecol Oncol; 1995 Feb; 56(2):175-80. PubMed ID: 7896181
[TBL] [Abstract][Full Text] [Related]
36. Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013.
Aoki D
J Obstet Gynaecol Res; 2014 Feb; 40(2):338-48. PubMed ID: 24472052
[TBL] [Abstract][Full Text] [Related]
37. Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
Hiura M; Nogawa T; Matsumoto T; Yokoyama T; Shiroyama Y; Wroblewski J
Int J Gynecol Cancer; 2010 Aug; 20(6):1000-5. PubMed ID: 20683408
[TBL] [Abstract][Full Text] [Related]
38. Validation of tumor size as staging variable in the revised International Federation of Gynecology and Obstetrics stage I leiomyosarcoma: a population-based study.
Garg G; Shah JP; Liu JR; Bryant CS; Kumar S; Munkarah A; Morris RT
Int J Gynecol Cancer; 2010 Oct; 20(7):1201-6. PubMed ID: 20940535
[TBL] [Abstract][Full Text] [Related]
39. A prognostic system for epithelial ovarian carcinomas using machine learning.
Grimley PM; Liu Z; Darcy KM; Hueman MT; Wang H; Sheng L; Henson DE; Chen D
Acta Obstet Gynecol Scand; 2021 Aug; 100(8):1511-1519. PubMed ID: 33665831
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.
Kuhn W; Rutke S; Späthe K; Schmalfeldt B; Florack G; von Hundelshausen B; Pachyn D; Ulm K; Graeff H
Cancer; 2001 Nov; 92(10):2585-91. PubMed ID: 11745193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
